Women Home Based Workers in Rural areas of Pakistan

Home-based work is a “general category of work within the informal or unorganized sector where workers carry out remunerative activities within their homes or in the surrounding areas but not at the premises of an employer”. The women Home-based workers defines as “The Women who work in their own dwelling or home stations. It is the moneymaking activity. The home based work includes the embroidery, handicrafts, stitching, weaving, shoe making, football making, garments, handmade jewelry and decoration piece making etc. The main purpose of this study was to explore awareness among women home based worker about their rights. The study was conducted in District Faisalabad. Multistage sampling technique was used in this study. At first stage, one Tehsil Faisalabad out of five Tehsils was selected by using simple random sampling technique. At second stage 4 union councils including UC-49, UC-157, and UC-274 were selected by using simple purposive sampling technique. At third stage four villages from each union council out of five villages (Chack No- 225 RB, Malkhawala), (Chack No-217 RB, Chakaira), (Chack No-218 RB, Pronkawala) and (Chack No-61 JB, Dharora) were selected purposively. The study was conducted in rural area of District Faisalabad. The sample size of one twenty women was selected by using simple random sampling.  Questionnaire was used as a tool for data collection and collected data were analyzed by using Statistical Package for Social Sciences (SPSS). Results of the study revealed that 61.7% of the respondents were illiterate, about 38.3% of the respondents earned 2501-5000 rupees, the significant majority 86.7% of the respondents belonged to lower class, about one third 40% of the respondents involved in stitching, more than half 51.7% of the respondents worked up to 6 hours per day, the majority 67.5% the of the respondents had muscular pain, and the significant majority 87.5% of the respondents had no awareness about their rights

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570